Bradley Merrill Thompson | Healthcare IT News

Bradley Merrill Thompson

Motor vehicles stalled in a traffic jam

Commentary: Digital health companies should stay away from FDA in 2021

By Bradley Merrill Thompson 05:20 pm December 23, 2020

As the agency's workload swells with the weight of a public health emergency, digital health companies on a timeline should consider whether their products truly warrant a regulatory submission, writes Epstein Becker & Green's Bradley Merrill Thompson.

More Stories

Stethoscope on tablet

HIMSSCast: The next big investment in patient experience is the CRM

Rami Karjian at LeanTaaS_Team of surgeons Photo by Hispanolistic/E+/Getty Images

Addressing OR disruption with predictive analytics

Person sits at table with a laptop while holding a pill bottle

Direct-to-patient platform uses AI to find gaps in care

Clinical care collaboration

ATA launches Center of Digital Excellence with health system heavy-hitters

Lee Kim at HIMSS_Healthcare Cybersecurity Forum 2024

Governance remains a significant cybersecurity weak point

Michael Meucci of Arcadia on AI

AI is shifting from novelty to a critical resource, embedded in healthcare

Nursing executives huddle with staff and discuss data on a tablet.

Roundup: New tools aim to give clinicians what they need with AI

Healthcare worker with tablet looking at data displays

Create a center of excellence to maximize the ROI of AI investments